These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12812007)

  • 1. Dealing with uncertainty in drug safety: lessons for the future from sertindole.
    Waller P
    Pharmacoepidemiol Drug Saf; 2003 Jun; 12(4):283-7; discussion 289-90. PubMed ID: 12812007
    [No Abstract]   [Full Text] [Related]  

  • 2. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole.
    Moore N; Hall G; Sturkenboom M; Mann R; Lagnaoui R; Begaud B
    Pharmacoepidemiol Drug Saf; 2003 Jun; 12(4):271-81. PubMed ID: 12812006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sertindole: dilemmas for its use in clinical practice.
    Pae CU
    Expert Opin Drug Saf; 2013 May; 12(3):321-6. PubMed ID: 23432404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
    Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
    Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.
    Kasper S; Möller HJ; Hale A
    Eur Arch Psychiatry Clin Neurosci; 2010 Feb; 260(1):59-68. PubMed ID: 19455275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole.
    Lindström E; Farde L; Eberhard J; Haverkamp W
    Int J Neuropsychopharmacol; 2005 Dec; 8(4):615-29. PubMed ID: 15963244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sertindole on QTD and TPTE.
    Nielsen J; Andersen MP; Graff C; Kanters JK; Hardahl T; Dybbro J; Struijk JJ; Meyer JM; Toft E
    Acta Psychiatr Scand; 2010 May; 121(5):385-8. PubMed ID: 20085555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sertindole causes distinct electrocardiographic T-wave morphology changes.
    Nielsen J; Graff C; Hardahl T; Andersen MP; Kristoffersen J; Struijk JJ; Toft E; Meyer JM
    Eur Neuropsychopharmacol; 2009 Oct; 19(10):702-7. PubMed ID: 19457646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sertindole on QTc interval in patients with schizophrenia.
    Atmaca M; Yavuzkir M; Mermi O; Topuz M; Kanmaz E; Tezcan E
    Neurosci Lett; 2008 Sep; 442(1):1-3. PubMed ID: 18639380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Loss of consciousness during treatment with sertindole].
    Haberfellner EM
    Psychiatr Prax; 1999 May; 26(3):150. PubMed ID: 10412716
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug safety and efficacy evaluation of sertindole for schizophrenia.
    Karamatskos E; Lambert M; Mulert C; Naber D
    Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
    Thomas SH; Drici MD; Hall GC; Crocq MA; Everitt B; Lader MH; Le Jeunne C; Naber D; Priori S; Sturkenboom M; Thibaut F; Peuskens J; Mittoux A; Tanghøj P; Toumi M; Moore ND; Mann RD
    Acta Psychiatr Scand; 2010 Nov; 122(5):345-55. PubMed ID: 20384598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked elevation of creatine kinase with sertindole: a case report.
    Oulis P; Koulouris GC; Konstantakopoulos G; Masdrakis VG
    Pharmacopsychiatry; 2007 Nov; 40(6):295-6. PubMed ID: 18030658
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of sertindole in schizophrenia: a clinical review.
    Zoccali RA; Bruno A; Muscatello MR
    J Clin Psychopharmacol; 2015 Jun; 35(3):286-95. PubMed ID: 25830594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ejaculatory dysfunction in patient with schizophrenia on sertindole.
    Jukić MK; Drmić S; Mimica N
    Psychiatr Danub; 2010 Mar; 22(1):128-31. PubMed ID: 20305609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sertindole and impaired atrioventricular function, in the absence of Q-T prolongation: a case report.
    Rizos EN; Leftheriotis D; Douzenis A; Chatziioannou S; Siafakas N; Nika S; Kremastinos D; Lykouras L
    Psychiatry Clin Neurosci; 2010 Aug; 64(4):442. PubMed ID: 20653911
    [No Abstract]   [Full Text] [Related]  

  • 17. The European sertindole safety and exposure survey: a follow-up study of 8600 patients.
    Peuskens J; Moore N; Azorin JM; Toumi M; Cochran J
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):804-11. PubMed ID: 17551996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxetine discontinuation syndrome in association with sertindole therapy.
    Walker-Kinnear M; McNaughton S
    Br J Psychiatry; 1997 Apr; 170():389. PubMed ID: 9246265
    [No Abstract]   [Full Text] [Related]  

  • 19. Do we need another atypical antipsychotic?
    Kasper S
    Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S146-52. PubMed ID: 18511242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sertindole hydrochloride: a novel antipsychotic medication with a favorable side effect profile.
    Brown GR; Radford JM
    South Med J; 1997 Jul; 90(7):691-3. PubMed ID: 9225889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.